News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 109–144
- Matches
- 841
- Sources here
- 23
- Companies here
- 18
Search results
Stored financial headlines
Active search
841 matching headlines
Ticker or company: NOSMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Insight Molecular Diagnostics signals ~$8M quarterly cash burn in H2 2026 while targeting FDA authorization later this year
Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q2 2026 MANAGEMENT VIEW * "It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx" (President, CEO & Director Joshua Riggs), adding, "We continue to target receipt …
IMDX
main company
Sharemaestro market context
Price below Trend Line
52 weeks +66.8%
Innospec (IOSP) Is Up 7.5% After Debt-Free, Higher-Margin Q2 2026 Earnings Report – What’s Changed?
Innospec (IOSP) reported strong Q2 2026 results with sales rising to US$491.4 million and net income to US$30.8 million, driven by improved earnings and a debt-free balance sheet. This performance, coupled with a US$75 million share repurchase authorization, reinforces the company's financial flexibility, though …
IOSP
main company
Sharemaestro market context
Trend signal active
52 weeks +10.3%
Co-Diagnostics (NASDAQ: CODX) sees Jane Street disclose 1.7% equity stake
Jane Street Group, LLC and its subsidiaries, Jane Street Capital, LLC and Jane Street Global Trading, LLC, have disclosed a 1.7% equity stake in Co-Diagnostics, Inc. (NASDAQ: CODX). This ownership amounts to 89,240 shares of common stock, held with shared voting and dispositive power. …
CODX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -85.4% · Next-week setup negative 40.9%
IONOS Group SE (WBO:IOS) (Q2 2026) Earnings Call Highlights: Record Customer Growth and AI ...
This article first appeared on GuruFocus. Total Revenue (H1 2026): EUR701 million, up 6.9% year-over-year (8.2% constant currency). Q2 Revenue Growth: Up 8.1% year-over-year (8.8% constant currency). Adjusted EBITDA (H1 2026): EUR245 million, with a 35% margin (down from 36.1% in the prior year …
Sharemaestro market context Trend signal active 52 weeks -10.5% · Next-week setup positive 57.3%Sonos (NasdaqGS:SONO) Stock Forecast & Analyst Predictions
Sonos (SONO) is projected to experience significant earnings growth of 23.2% per year and revenue growth of 6.7% per year, with an EPS growth rate of 26.4% annually. Analysts have recently revised EPS estimates upwards for fiscal year 2026 and expect a high return …
SONO
main company
Sharemaestro market context
Trend signal started
52 weeks +23.0%
Lucid Diagnostics Inc expected to post a loss of 7 cents a share - Earnings Preview
Lucid Diagnostics Inc is anticipated to report a loss of 7 cents per share in its upcoming earnings announcement. This preview indicates the company's expected financial performance for the period.
LUCD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -12.0%
Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results
* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …
IMDX
main company
Sharemaestro market context
Price below Trend Line
52 weeks +66.8%
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates
Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …
IMDX
main company
Sharemaestro market context
Price below Trend Line
52 weeks +66.8%
Insight Molecular Diagnostics: Q2 Earnings Snapshot
The provided content is not an article but rather a privacy notice or a placeholder. It does not contain any information about Insight Molecular Diagnostics or its Q2 earnings. Therefore, no meaningful summary can be generated.
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1%Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com
This article announces the filing of a Form 8K by Insight Molecular Diagnostics Inc. on August 10. The filing is a standard regulatory announcement, and the article provides no further details beyond the company name and filing date. It appears to be a placeholder …
IMDX
main company
Sharemaestro market context
Price below Trend Line
52 weeks +66.8%
Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash
Insight Molecular Diagnostics (IMDX) reported a steep revenue drop in Q2 2026, with net revenue down sharply to $239,000 from $518,000 in the prior year, and a net loss of $11.3 million. Despite the revenue decline and increased operating expenses, the company bolstered its …
IMDX
main company
Sharemaestro market context
Price below Trend Line
52 weeks +66.8%
Sonos (Nasdaq:SONO) - Stock Analysis
This Simply Wall St analysis provides a comprehensive overview of Sonos (NASDAQ: SONO), covering its valuation, growth prospects, past performance, financial health, and dividend policy. The report highlights that Sonos is trading below its estimated fair value, with earnings projected to grow by 23.18% …
SONO
main company
Sharemaestro market context
Trend signal started
52 weeks +23.0%
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
Insight Molecular Diagnostics Inc. (IMDX) reported its Q2 2026 results and provided an update on the FDA review of its GraftAssureDx product. The company is progressing with the FDA, expecting marketing authorization soon, and highlighted favorable Medicare reimbursement policy changes. IMDX also shared clinical …
IMDX
main company
Sharemaestro market context
Price below Trend Line
52 weeks +66.8%
Cronos Group Inc. stock falls Monday, underperforms market
Cronos Group Inc. (CRON) stock decreased by 3.23% to $3.00 on Monday, underperforming the broader market. This drop ended a two-day winning streak for the company's shares. The NASDAQ Composite Index also fell 0.32%, and the Dow Jones Industrial Average fell 0.11%.
CRON
main company
Sharemaestro market context
Trend signal active
52 weeks +20.8%
Ainos scales AI Nose platform with 613M Smell ID records, boosting semiconductor sector growth potential.
Ainos, Inc. is significantly advancing its AI Nose platform by accumulating 613 million Smell ID data records, primarily from semiconductor manufacturing since December 2025. This expanding dataset enhances the platform's scent recognition capabilities and supports its scaling into broader industrial applications. The company also …
AIMD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -60.1% · Next-week setup negative 42.2%
Ainos' AI Nose Has a $2.1M Semiconductor Backlog
Ainos (NASDAQ:AIMD) announced that a VASRO report highlights its AI Nose platform's progress in semiconductor deployments, accumulating 613 million industrial Smell ID data records since December 2025. The report notes a $2.1 million AI Nose subscription backlog from a semiconductor customer, with $350,000 prepaid, …
AIMD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -60.1% · Next-week setup negative 42.2%
IMDX Stock Price and Chart — NASDAQ:IMDX
This article provides an overview of Insight Molecular Diagnostics Inc. (IMDX) stock, including its current price, market capitalization, key financial stats, and performance over various periods. It also highlights analyst opinions, future earnings expectations, and company details, noting the FDA review for GraftAssureDx and …
IMDX
main company
Sharemaestro market context
Price below Trend Line
52 weeks +66.8%
VASRO Research Highlights Ainos' Progress in Scaling Smell AI Commercialization and Compounding Its Smell ID Dataset
Ainos, Inc. announced that VASRO GmbH published a new report detailing Ainos' advancements in commercializing its AI Nose platform. The report highlights the accumulation of 613 million industrial Smell ID data records, primarily from semiconductor manufacturing, and discusses a $2.1 million AI Nose subscription …
AIMD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -60.1% · Next-week setup negative 42.2%
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates By Investing.com
Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …
IMDX
main company
Sharemaestro market context
Price below Trend Line
52 weeks +66.8%
Price to sales forward of Lucid Diagnostics Inc. – NASDAQ:LUCD
This page displays the "Price to sales forward" financial metric for Lucid Diagnostics Inc. (NASDAQ: LUCD). It indicates that the market is closed, with no trades currently. The information is provided by TradingView, with market data from ICE Data Services and reference data from …
LUCD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -12.0%
IVY LANE CAPITAL MANAGEMENT, LLC's Quest Diagnostics Inc(DGX) Holding History
This article details IVY LANE CAPITAL MANAGEMENT, LLC's historical holdings in Quest Diagnostics Inc (DGX). As of March 31, 2026, the firm holds 29,000 shares valued at $5.68 million, representing 8.59% of its portfolio. The investment has generated an estimated gain of $4.19 million, …
DGX
main company
Sharemaestro market context
Trend signal active
52 weeks +31.8% · Next-week setup positive 58.1%
Ainos Inc (AIMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Ainos Inc (AIMD), focusing on future EPS and revenue growth estimates. It lists the current stock price and market capitalization, along with navigation options for news, financials, technical analysis, and dividend information. The page also includes a …
AIMD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -60.1% · Next-week setup negative 42.2%